Phenergan and Aggrenox drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Phenergan (promethazine hydrochloride) and Aggrenox (aspirin; dipyridamole). Common drug interactions include abdominal pain among females and gastric ulcer among males.

The phase IV clinical study analyzes what interactions people have when they take Phenergan and Aggrenox. It is created by eHealthMe based on reports of 22 people who take the same drugs from the FDA, and is updated regularly.

What is Phenergan?

Phenergan has active ingredients of promethazine hydrochloride. It is often used in nausea. eHealthMe is studying from 25,312 Phenergan users. Check the latest studies of Phenergan.

What is Aggrenox?

Aggrenox has active ingredients of aspirin; dipyridamole. It is often used in stroke. eHealthMe is studying from 7,654 Aggrenox users. Check the latest studies of Aggrenox.



On Jul, 15, 2026

22 people who take Phenergan and Aggrenox together, and have interactions are studied.

Phenergan and Aggrenox drug interactions.

What are the common drug interactions of Phenergan and Aggrenox, by gender? *:

female:

  1. Abdominal pain
  2. Anaemia (lack of blood)
  3. Aortic stenosis (obstruction to the outflow of blood from the left ventricle into the aorta)
  4. Aplasia pure red cell (type of anaemia affecting the precursors to red blood cells but not to white blood cells)
  5. Balance disorder
  6. Cardiogenic shock (inadequate circulation of blood)
  7. Cholecystitis acute (rapid infection of gallbladder)
  8. Clostridium difficile colitis (inflammation of colon by clostridium difficile bacteria infection)
  9. Cognitive disorder (mental health disorders affects learning, memory, perception, and problem solving)
  10. Congestive cardiomyopathy (weakening of heart muscle)

male:

  1. Gastric ulcer (stomach ulcer)
  2. Haematemesis (vomiting of blood)
  3. Upper gastrointestinal haemorrhage (upper gastrointestinal bleeding)
  4. Pleural effusion (water on the lungs)
  5. Thrombosis (formation of a blood clot inside a blood vessel)

What are the common drug interactions of Phenergan and Aggrenox, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Anaemia (lack of blood)
  2. Bladder dilatation
  3. Catheter site infection (infection at the site of insertion)
  4. Culture urine positive
  5. Diarrhoea
  6. Drug ineffective
  7. Dysphagia (a condition in which swallowing is difficult or painful)
  8. Dyspnoea (difficult or laboured respiration)
  9. Emotional distress
  10. Extrapyramidal disorder (involuntary muscle spasms in the face and neck)

60+:

  1. Sepsis (a severe blood infection that can lead to organ failure and death)
  2. Gastric ulcer (stomach ulcer)
  3. Clostridium difficile colitis (inflammation of colon by clostridium difficile bacteria infection)
  4. Congestive cardiomyopathy (weakening of heart muscle)
  5. Dyspnoea (difficult or laboured respiration)
  6. Enterovesical fistula
  7. Hyperbilirubinaemia (excess of bilirubin in the blood)
  8. Hyperkalaemia (damage to or disease of the kidney)
  9. Hypotension (abnormally low blood pressure)
  10. Ischaemic hepatitis (decreased blood supply to the liver resulting in injury to liver cells)

What are the existing conditions these people have? *

  1. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 18.18%
  2. Pain: 3 people, 13.64%
  3. Nausea And Vomiting: 3 people, 13.64%
  4. High Blood Pressure: 3 people, 13.64%
  5. Heart Attack: 3 people, 13.64%
  6. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 13.64%
  7. Constipation: 3 people, 13.64%
  8. Transient Ischaemic Attack (a transient episode of neurologic dysfunction caused by ischemia (loss of blood flow)): 2 people, 9.09%
  9. Osteoporosis (bones weak and more likely to break): 2 people, 9.09%
  10. Migraine (headache): 2 people, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Phenergan and Aggrenox?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Phenergan and Aggrenox:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Phenergan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Aggrenox:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Phenergan and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Aggrenox and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on promethazine hydrochloride and aspirin; dipyridamole (the active ingredients of Phenergan and Aggrenox, respectively), and Phenergan and Aggrenox (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: